Form 4: LAVA Therapeutics Director Exits Options for Cash, CVRs

LAVA Therapeutics NV Director Jay T. Backstrom cancelled 33,390 share options in exchange for cash and contingent value rights as part of a purchase agreement.

Summary

• Director Jay T. Backstrom of LAVA Therapeutics NV cancelled 33,390 share options.
• The options had an exercise price of $0.93 per share.
• The cancellation was in exchange for cash and Contingent Value Rights (CVRs).
• The cash component was calculated as the excess of $1.04 over the exercise price, multiplied by the number of shares, totaling $3,672.90 (net of taxes and deductions).
• Backstrom also received one CVR per underlying share, totaling 33,390 CVRs.
• This transaction was pursuant to a Purchase Agreement dated August 3, 2025, between LAVA Therapeutics NV and XOMA Royalty Corporation.
• Following the transaction, Backstrom beneficially owns 0 derivative securities.

Sentiment

Score: 6

Explanation: Neutral to slightly positive for the reporting person, as they monetized in-the-money options and received CVRs. For the company, it represents a standard transaction related to a prior agreement, not inherently positive or negative on its own.

Positives

• The director received cash and CVRs for in-the-money options, realizing value from their equity holdings.
• The transaction simplifies the director's equity holdings by converting options into a defined cash and CVR package.

Negatives

• The director no longer holds direct equity options in the company, potentially reducing direct alignment with future stock price appreciation beyond the CVRs.
• The cash received is relatively small ($3,672.90), indicating a modest gain on these specific options.

Future Outlook

No forward-looking statements or guidance are provided in this filing.

Industry Context

This transaction is an insider filing detailing a director's equity compensation adjustment, specifically the cancellation of options in exchange for cash and CVRs, as a result of a previously established Purchase Agreement with XOMA Royalty Corporation. It does not provide broader industry context or trends.

Comparison to Industry Standards

• This is a specific insider transaction related to a corporate agreement and is not directly comparable to industry-wide financial results or operational benchmarks. The terms of the option cancellation (cash plus CVRs) are unique to the underlying Purchase Agreement between LAVA Therapeutics NV and XOMA Royalty Corporation.

Stakeholder Impact

• Shareholders: The direct impact on existing shareholders from this specific Form 4 filing is minimal, as it details a director's monetization of existing options as part of a larger, previously announced corporate agreement. The underlying Purchase Agreement with XOMA Royalty Corporation would have a more significant impact.
• Reporting Person (Jay T. Backstrom): Realized a cash gain and received CVRs, converting potential future equity upside into a more defined value.

Next Steps

• The value of the Contingent Value Rights (CVRs) will depend on future events as defined in the Purchase Agreement.

Key Dates

Recommendation

This Form 4 filing details an insider transaction where a director monetized existing options as part of a pre-announced purchase agreement. It does not provide new fundamental information about the company's operations, financial performance, or strategic direction that would warrant a change in investment recommendation. The transaction is an expected outcome of a prior corporate agreement. Therefore, a 'hold' recommendation is appropriate as there's no new information to significantly alter the investment thesis.

Keywords

LAVA Therapeutics, LVTX, SEC Form 4, Insider Transaction, Option Cancellation, Contingent Value Rights, CVRs, Director Holdings, Equity Compensation, XOMA Royalty Corporation